Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
HDAC Inhibitors Repress NUT Carcinoma Programs
2026-10-06
Shiota et al. used a dCas9-based transcriptional reporter screen to identify structurally diverse HDAC inhibitors that suppress NUT-driven transcription. The study connects HDAC inhibition with loss of BRD4-NUT megadomain activity, tumor-cell differentiation, and growth control, while also showing enhanced effects when combined with bromodomain inhibition in xenograft models.
-
Exogenous NADH Potentiates Antibiotics Against E. tarda
2026-10-06
A 2024 Virulence study reports that exogenous NADH reprogrammed Edwardsiella tarda metabolism, increased ATP-associated energy metabolism, and strengthened neomycin activity. The findings support metabolic potentiation as a research strategy, but the evidence remains primarily culture-based and requires validation across strains, hosts, exposure contexts, and safety endpoints.
-
Grazoprevir Hydrate: From Protease Biology to Translation
2026-10-05
A source-grounded perspective on Grazoprevir hydrate and MK-5172 hydrate, connecting NS3/4A protease biology with genotype-aware validation, resistance research, and translational strategy.
-
DRB: Research Context, Mechanisms, and Limits
2026-10-05
DRB is a research compound used to study transcriptional elongation and cyclin-dependent kinase activity. This overview compares supplier-reported biochemical and cellular findings with peer-reviewed evidence on YTHDF1-driven stem-cell fate transitions, emphasizing mechanistic boundaries, evidence strength, and the absence of direct evidence connecting DRB to that transdifferentiation model.
-
Parthenolide, ROS, and Lymphoid Cancer Apoptosis
2026-10-04
Jorge and colleagues used a resazurin-based cell viability assay alongside flow cytometry and gene-expression analysis to examine parthenolide responses across seven lymphoid malignancy cell lines. The study links reduced metabolic activity with apoptosis, oxidative stress, glutathione loss, and mitochondrial membrane-potential disruption, while showing that response mechanisms vary by cell line.
-
AO/PI Staining Solution for Mechanistic Cell Counting
2026-10-03
AO/PI Staining Solution provides a membrane-integrity view of cell populations that can strengthen interpretation of diabetic nephropathy research. This article connects fluorescent live/dead measurements with the phillygenin study while clarifying what the assay can—and cannot—prove about inflammation and apoptosis.
-
β-Pseudouridine: Designing Causal RNA Assays
2026-10-02
β-Pseudouridine is a C-glycoside isomer of uridine with important effects on RNA structure and translational fidelity. This article develops a causal assay framework for distinguishing nucleoside chemistry from RNA platform effects, using recent self-amplifying influenza vaccine findings as a practical case study.
-
SARS-CoV-2 Release Factors Revealed by RNAi
2026-10-01
Kerr et al. used an arrayed, druggable-genome RNA interference screen with two-timepoint viral RNA measurements to identify host factors acting across the SARS-CoV-2 replication and reinfection cycle. The study gives particular weight to Rab11a-linked vesicular transport and shows that pharmacological CDK9 inhibition can block viral release, while also clarifying the limitations of translating host-factor screens into antiviral strategies.
-
2,2,2-Trichloroethanol in Protein Workflows
2026-10-01
Use 2,2,2-Trichloroethanol as a flexible protein analysis reagent for rapid in-gel visualization, assay development, and molecular biology research. This guide connects practical electrophoresis optimization with the orthogonal imaging strategy reported for assessing dopaminergic neuron maturation in a Parkinson’s disease model.
-
Fluorescein TSA Fluorescence System Kit Guide
2026-09-30
The Fluorescein TSA Fluorescence System Kit provides a spatially precise strategy for detecting scarce targets in fixed retinal and vascular samples. This guide connects tyramide chemistry with the blood–retinal barrier findings of a mechanistic diabetic retinopathy study and explains how to design, control, and interpret amplified fluorescence assays.
-
X-Gal: Reliable β-Galactosidase Workflows
2026-09-30
A scenario-based guide to selecting, preparing, and interpreting X-Gal in blue-white colony screening and β-galactosidase activity assays. It explains how SKU A2539 supports reproducible molecular cloning while clarifying the limits of using a chromogenic reporter as a proxy for cell viability or cytotoxicity.
-
Bromodomain Inhibitor (+)-JQ1: Mechanism & Uses
2026-09-29
Bromodomain Inhibitor, (+)-JQ1 is a selective BET bromodomain inhibitor used to study BRD4, BRDT, transcriptional control, apoptosis, inflammation, and spermatogenesis. Its strongest use is as a mechanistic research probe, not as a validated clinical treatment.
-
Cannabidiol in Orofacial Inflammatory Pain
2026-09-29
A 2026 Brain Research Bulletin study shows that cannabidiol can reduce both inflammatory orofacial nociception and pain-associated affective and cognitive deficits in mice. Its main contribution is a compartment-specific mechanism linking peripheral CB2 activity, central CB1 signaling, endocannabinoid changes, and serotonin dynamics in the central amygdala.
-
Novobiocin: Mechanism, Evidence, and Protocols
2026-09-28
Novobiocin is an aminocoumarin antibiotic that inhibits bacterial DNA gyrase subunit B and modulates Hsp90. Evidence also supports its evaluation as an antiparasitic agent and antiviral compound, but antiviral findings remain in vitro and should not be treated as clinical efficacy.
-
GS967: Cardiac Late Sodium Current Inhibitor
2026-09-28
GS967 is a potent cardiac late sodium current inhibitor used to study pathological sodium influx, cellular calcium loading, and cardiac electrophysiology. Product information reports activity in ventricular myocytes and isolated hearts, while aging-mouse research supports late sodium current as a mechanism linking delayed repolarization with impaired relaxation.